pcDNA3.1-hACE2 Citations (21)
Originally described in: Structural basis of receptor recognition by SARS-CoV-2.Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F Nature. 2020 Mar 30. pii: 10.1038/s41586-020-2179-y. doi: 10.1038/s41586-020-2179-y. PubMed Journal
Articles Citing pcDNA3.1-hACE2
| Articles |
|---|
Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models.
Li X, Lidsky P, Xiao Y, Wu CT, Garcia-Knight M, Yang J, Nakayama T, Nayak JV, Jackson PK, Andino R, Shu X.
bioRxiv. 2020 Oct 28. doi: 10.1101/2020.10.28.359042.
PubMed
Associated Plasmids |
| Plasma ACE2 species are differentially altered in COVID-19 patients. Garcia-Ayllon MS, Moreno-Perez O, Garcia-Arriaza J, Ramos-Rincon JM, Cortes-Gomez MA, Brinkmalm G, Andres M, Leon-Ramirez JM, Boix V, Gil J, Zetterberg H, Esteban M, Merino E, Saez-Valero J. FASEB J. 2021 Aug;35(8):e21745. doi: 10.1096/fj.202100051R. PubMed |
| Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. Li X, Lidsky P, Xiao Y, Wu CT, Garcia-Knight M, Yang J, Nakayama T, Nayak JV, Jackson PK, Andino R, Shu X. PLoS Pathog. 2021 Sep 3;17(9):e1009898. doi: 10.1371/journal.ppat.1009898. PubMed |
| Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells. Youn JY, Zhang Y, Wu Y, Cannesson M, Cai H. Redox Biol. 2021 Oct;46:102099. doi: 10.1016/j.redox.2021.102099. Epub 2021 Aug 17. PubMed |
| N-Terminal Modification of Gly-His-Tagged Proteins with Azidogluconolactone. Brune KD, Lieknina I, Sutov G, Morris AR, Jovicevic D, Kalnins G, Kazaks A, Kluga R, Kastaljana S, Zajakina A, Jansons J, Skrastina D, Spunde K, Cohen AA, Bjorkman PJ, Morris HR, Suna E, Tars K. Chembiochem. 2021 Nov 16;22(22):3199-3207. doi: 10.1002/cbic.202100381. Epub 2021 Oct 6. PubMed |
| Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19. Shin J, Toyoda S, Nishitani S, Fukuhara A, Kita S, Otsuki M, Shimomura I. Diabetes. 2021 Dec;70(12):2745-2755. doi: 10.2337/db20-1094. Epub 2021 Oct 6. PubMed |
| DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. Villa A, Brunialti E, Dellavedova J, Meda C, Rebecchi M, Conti M, Donnici L, De Francesco R, Reggiani A, Lionetti V, Ciana P. Pharmacol Res. 2022 Jan;175:105982. doi: 10.1016/j.phrs.2021.105982. Epub 2021 Nov 16. PubMed |
| H2S protects from oxidative stress-driven ACE2 expression and cardiac aging. Barrow K, Wang Y, Yu R, Zhu J, Yang G. Mol Cell Biochem. 2022 May;477(5):1393-1403. doi: 10.1007/s11010-022-04386-4. Epub 2022 Feb 11. PubMed |
| Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2. Francesconi O, Donnici L, Fragai M, Pesce E, Bombaci M, Fasciani A, Manganaro L, Conti M, Grifantini R, De Francesco R, Nativi C, Roelens S. iScience. 2022 May 20;25(5):104239. doi: 10.1016/j.isci.2022.104239. Epub 2022 Apr 11. PubMed |
| SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Shah M, Ung Moon S, Hyun Kim J, Thanh Thao T, Goo Woo H. Comput Struct Biotechnol J. 2022;20:2042-2056. doi: 10.1016/j.csbj.2022.04.030. Epub 2022 Apr 26. PubMed |
| Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Torres JL, Ozorowski G, Andreano E, Liu H, Copps J, Piccini G, Donnici L, Conti M, Planchais C, Planas D, Manganaro N, Pantano E, Paciello I, Pileri P, Bruel T, Montomoli E, Mouquet H, Schwartz O, Sala C, De Francesco R, Wilson IA, Rappuoli R, Ward AB. Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2120976119. doi: 10.1073/pnas.2120976119. Epub 2022 May 12. PubMed |
| SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. Vanhulle E, Stroobants J, Provinciael B, Camps A, Noppen S, Maes P, Vermeire K. Antiviral Res. 2022 Jul;203:105342. doi: 10.1016/j.antiviral.2022.105342. Epub 2022 May 18. PubMed |
| Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. Andreano E, Paciello I, Marchese S, Donnici L, Pierleoni G, Piccini G, Manganaro N, Pantano E, Abbiento V, Pileri P, Benincasa L, Giglioli G, Leonardi M, Maes P, De Santi C, Sala C, Montomoli E, De Francesco R, Rappuoli R. Nat Commun. 2022 Jun 13;13(1):3375. doi: 10.1038/s41467-022-31115-8. PubMed |
| Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells. Aicher SM, Streicher F, Chazal M, Planas D, Luo D, Buchrieser J, Nemcova M, Seidlova V, Zukal J, Serra-Cobo J, Pontier D, Pain B, Zimmer G, Schwartz O, Roingeard P, Pikula J, Dacheux L, Jouvenet N. J Virol. 2022 Jul 27;96(14):e0060822. doi: 10.1128/jvi.00608-22. Epub 2022 Jul 5. PubMed |
| DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model. Compagnone M, Pinto E, Salvatori E, Lione L, Conforti A, Marchese S, Rava M, Ryan K, Hall Y, Rayner E, Salguero FJ, Paterson J, Iannacone M, De Francesco R, Aurisicchio L, Palombo F. Vaccines (Basel). 2022 Jul 25;10(8):1178. doi: 10.3390/vaccines10081178. PubMed |
| Memory CD8(+) T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. Brasu N, Elia I, Russo V, Montacchiesi G, Stabile SA, De Intinis C, Fesi F, Gizzi K, Macagno M, Montone M, Mussolin B, Grifoni A, Faravelli S, Marchese S, Forneris F, De Francesco R, Sette A, Barnaba V, Sottile A, Sapino A, Pace L. Nat Immunol. 2022 Oct;23(10):1445-1456. doi: 10.1038/s41590-022-01313-z. Epub 2022 Sep 22. PubMed |
| Spike protein receptor-binding domains from SARS-CoV-2 variants of interest bind human ACE2 more tightly than the prototype spike protein. Charles J, McCann N, Ploplis VA, Castellino FJ. Biochem Biophys Res Commun. 2023 Jan 22;641:61-66. doi: 10.1016/j.bbrc.2022.12.011. Epub 2022 Dec 5. PubMed |
| B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response. Andreano E, Paciello I, Pierleoni G, Piccini G, Abbiento V, Antonelli G, Pileri P, Manganaro N, Pantano E, Maccari G, Marchese S, Donnici L, Benincasa L, Giglioli G, Leonardi M, De Santi C, Fabbiani M, Rancan I, Tumbarello M, Montagnani F, Sala C, Medini D, De Francesco R, Montomoli E, Rappuoli R. Nat Commun. 2023 Jan 4;14(1):53. doi: 10.1038/s41467-022-35781-6. PubMed |
| Comparison of truncated human angiotensin-converting enzyme 2 (hACE2) expression in pET28a(+) versus pET-SUMO vector and two Escherichia coli strains. Baciu DD, Dinu S, Palade B, Onu A, Costache A. Adv Med Sci. 2023 Mar;68(1):61-70. doi: 10.1016/j.advms.2023.01.001. Epub 2023 Feb 4. PubMed |
| SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Martinez-Marmol R, Giordano-Santini R, Kaulich E, Cho AN, Przybyla M, Riyadh MA, Robinson E, Chew KY, Amor R, Meunier FA, Balistreri G, Short KR, Ke YD, Ittner LM, Hilliard MA. Sci Adv. 2023 Jun 9;9(23):eadg2248. doi: 10.1126/sciadv.adg2248. Epub 2023 Jun 7. PubMed |
| ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection. Engler M, Albers D, Von Maltitz P, Gross R, Munch J, Cirstea IC. Life Sci Alliance. 2023 Jul 4;6(9):e202201880. doi: 10.26508/lsa.202201880. Print 2023 Sep. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.